Long-term survival data for nivolumab plus ipilimumab in first-line treatment of advanced or metastatic renal cell carcinoma presented at conference

Updated results from CheckMate-214 show the median overall survival (OS) was 48.1 months for intermediate- and poor-risk patients treated with the combination versus 26.6 months for sunitinib (HR 0.65; 95% CI 0.54-0.78), with a 4-year OS rate of 50% versus 35.8%, respectively.

Biospace Inc.